Various RCTs have individually discovered that HIF-PHIs substantially benefit iron regulation in treating anemia by decreasing hepcidin, transferrin saturation (TSAT), and ferritin while increasing transferrin and total iron-binding capacity (TIBC). The gene discussed is HAMP; the disease is anemia.